Subcellular remodeling as a viable target for the treatment of congestive heart failure

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 11, Issue 1, 2006, Pages 31-45

  Dhalla, Naranjan S ^a   Dent, Melissa R ^a   Tappia, Paramjit S ^a,b   Sethi, Rajat ^c   Barta, Judit ^a   Goyal, Ramesh K ^d  

^a ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c TEXAS A AND M UNIVERSITY   (United States)

^d L M COLLEGE OF PHARMACY   (India)

Author keywords

Cardiac drugs; Cardiac dysfunction; Cardiac hypertrophy; Cardiac remodeling; Congestive heart failure; Subcellular remodeling

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM ION; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PHOSPHOLIPASE; PROTEINASE;

ADRENERGIC SYSTEM; CALCIUM CELL LEVEL; CELL SHAPE; CELL SIZE; CONGESTIVE HEART FAILURE; ENDOCRINE DISEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HEART FUNCTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; METABOLIC DISORDER; MITOCHONDRION; MUSCLE FIBRIL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SARCOLEMMA; SARCOPLASMIC RETICULUM;

ANIMALS; CARDIOMEGALY; GENE EXPRESSION; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOFIBRILS; RENIN-ANGIOTENSIN SYSTEM; SARCOLEMMA; SARCOPLASMIC RETICULUM;

EID: 33645703028     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840601100103     Document Type: Review

References (260)

1. Dhalla NS, Afzal A, Beamish RE, et al. Pathophysiology of cardiac dysfunction in congestive heart failure. Can J Cardiol 9:873-887, 1993
2. Baig MK, Mahon N, McKenna WJ, et al. The pathophysiology of advanced heart failure. Am Heart J 135: S216-S230, 1998
3. Piano MR, Bondmass M, Schwertz DW. The molecular and cellular pathophysiology of heart failure. Heart Lung 27:3-19, 1998
4. Alpert NR, Mulieri LA, Warshaw D. The failing human heart. Cardiovasc Res 54:1-10, 2002
5. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 35:569-582, 2000
6. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hyperten 18:655-673, 2000
7. Hasenfuss G. Animal models of human cardiovascular disease, heart failure and hypertrophy. Cardiovasc Res 39:60-76, 1998
8. Onega Mateo A, De Artinano AA. Highlights on endothelins: A review. Pharmacol Res 36:339-351, 1997
9. Deten A, Volz HC, Briest W, et al. Differential cytokine expression in myocytes and non-myocytes after myocardial infarction in rats. Mol Cell Biochem 242:47-55, 2003
10. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol 34:1577-1584, 2002
11. Rouleau JL. The neurohormonal hypothesis and the treatment of heart failure. Can J Cardiol 12 (Suppl):3F-8F, 1996
12. Grossman W. Cardiac hypertrophy: Useful adaptation or pathologic process? Am J Med 69:576-584, 1980
13. Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 23:869-877, 1994
14. Packer M. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 20:248-254, 1992
15. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 82:1724-1729, 1990
16. Francis G, Goldsmith SR, Levine TB, et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 101:370-377, 1984
17. DiBiano R. The changing syndrome of heart failure: An annotated review as we approach the 21st century. J Hypertension 12 (Suppl 4):S73-S87, 1994
18. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81:1161-1172, 1990
19. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83:1849-1865, 1991
20. Sabbah HN, Goldstein S. Ventricular remodeling: Consequences and therapy. Eur Heart J 14 (Suppl C):24-29, 1993
21. Ju H, Zhao S, Jassal DS, et al. Effect of AT1 receptor blockade on cardiac collagen remodeling after myocardial infarction. Cardiovasc Res 35:223-232, 1997
22. Briest W, Holzl A, Rassler B, et al. Significance of matrix metalloproteinases in norepinephrine-induced remodelling of rat hearts. Cardiovasc Res 57:379-387, 2003
23. Langer GA, Frank JS, Philipson KD. Ultrastructure and calcium exchange of the sarcolemma, sarcoplasmic reticulum and mitochondria of the myocardium. Pharmacol Therap 16:331-376, 1982
24. Dhalla NS, Ziegelhoffer A, Harrow JA. Regulatory role of membrane systems in heart function. Can J Physiol Pharmacol 55:1211-1234, 1977
25. Carafoli E. The homeostasis of calcium in heart cells. J Mol Cell Cardiol 17:203-212, 1985
26. Dhalla NS, Das PK, Sharma GP. Subcellular basis of cardiac contractile failure. J Mol Cell Cardiol 10:363-385, 1978
27. Hess ML. Concise review: Subcellular function in the acutely failing myocardium. Circulatory Shock 6:119-136, 1979
28. Dhalla NS, Pierce GN, Panagia V, et al. Calcium movements in relation to heart function. Basic Res Cardiol 77:117-139, 1982
29. Carafoli E, Bing RJ. Myocardial failure. J Appl Cardiol 3:3-18, 1988
30. Dhalla NS, Dixon IM, Beamish RE. Biochemical basis of heart function and contractile failure. J Appl Cardiol 6:7-30, 1991
31. Dhalla NS, Wang X, Beamish RE. Intracellular calcium handling in normal and failing hearts. Exp Clin Cardiol 1:7, 1996
32. Davies CH, Harding SE, Poole-Wilson PA. Cellular mechanisms of contractile dysfunction in human heart failure. Eur Heart J 17:189-198, 1996
33. Palermo J, Gulick J, Colbert M, et al. Transgenic remodeling of the contractile apparatus in the mammalian heart. Circ Res 78:504-509, 1996
34. Hefti MA, Harder BA, Eppenberger HM, et al. Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol 29:2873-2892, 1997
35. Gwathmey JK, Slawsky MT, Hajjar RJ, et al. Role of intracellular calcium handling in force-interval relationships of human ventricular myocardium. J Clin Invest 85:1599-1613, 1990
36. Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 85:1046-1055, 1992
37. Bentivegna LA, Ablin LW, Kihara Y, et al. Altered calcium handling in left ventricular pressure-overload hypertrophy as detected with aequorin in the isolated, perfused ferret heart. Circ Res 69:1538-1545, 1991
38. Bailey BA, Houser SR. Calcium transients in feline left ventricular myocytes with hypertrophy induced by slow progressive pressure overload. J Mol Cell Cardiol 24:365-373, 1992
39. Bing OH, Brooks WW, Conrad CH, et al. Intracellular calcium transients in myocardium from spontaneously hypertensive rats during the transition to heart failure. Circ Res 68:1390-1400, 1991
40. Siri FM, Krueger J, Nordin C, et al. Depressed intracellular calcium transients and contraction in myocytes from hypertrophied and failing guinea pig hearts. Am J Physiol Heart Circ Physiol 261:H514-H530, 1991
41. 2+ handling. J Clin Invest 98:764-776, 1996
42. 2+ handling is an early manifestation of pressure-overload hypertrophy in rat hearts. Am J Physiol Heart Circ Physiol 271:H228-H234, 1996
43. Dhalla NS, Shao Q, Panagia V. Remodeling of cardiac membranes during the development of congestive heart failure. Heart Failure Reviews 2:261-272, 1998
44. Movsesian MA, Schwinger RH. Calcium sequestration by the sarcoplasmic reticulum in heart failure. Cardiovasc Res 37:352-359, 1998
45. Matsui H, MacLennan DH, Alpert NR, et al. Sarcoplasmic reticulum gene expression in pressure overload-induced cardiac hypertrophy in rabbit. Am J Physiol Cell Physiol 268:C252-C258, 1995
46. 2+ transport and mechanics in compensated pressure-overload hypertrophy and congestive heart failure. Circ Res 77:759-764, 1995
47. Feldman AM, Weinberg EO, Ray PE, et al. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res 73:184-192, 1993
48. Zarain-Herzberg A, Rupp H, Elimban V, et al. Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir. FASEB J 10:1303-1309, 1996
49. Ohkusa T, Hisamatsu Y, Yano M, et al. Altered cardiac mechanism and sarcoplasmic reticulum function in pressure overload-induced cardiac hypertrophy in rats. J Mol Cell Cardiol 29:45-54, 1997
50. Hisamatsu Y, Ohkusa T, Kihara Y, et al. Early changes in the functions of cardiac sarcoplasmic reticulum in volume-overloaded cardiac hypertrophy in rats. J Mol Cell Cardiol 29:1097-1109, 1997
51. Keller E, Bond M, Moravec CS. Progression of left ventricular hypertrophy does not change the sarcoplasmic reticulum calcium store in the spontaneously hypertensive rat heart. J Mol Cell Cardiol 29:461-469, 1997
52. 2+-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 92:3220-3228, 1995
53. 2+ transients in failing human myocardium assessed with ryanodine. J Mol Cell Cardiol 30:1285-1294, 1998
54. 2+-ATPase in failing and nonfailing human hearts. Cardiovasc Res 31:625-632, 1996
55. Meyer M, Schillinger W, Pieske B, et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92:778-784, 1995
56. 2+-ATPase in failing and nonfailing human myocardium. Circ Res 75:434-442, 1994
57. Aral M, Matsui H, Perisamy M. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res 74:555-564, 1994
58. 2+-ATPase activity and expression in ventricular myocardium of dogs with heart failure. Am J Physiol Heart Circ Physiol 273:H12-H18, 1997
59. 2+-ATPase in contractile dysfunction of myocytes in tachycardia-induced heart failure. Am J Physiol Heart Circ Physiol 275:H31-H40, 1998
60. Prestle J, Dieterich S, Preuss M, et al. Heterogeneous transmural gene expression of calcium-handling proteins and natriuretic peptides in the failing human heart. Cardiovasc Res 43:323-331, 1999
61. Pennock GD, Spooner PH, Summers CE, et al. Prevention of abnormal sarcoplasmic reticulum calcium transport and protein expression in post-infarction heart failure using 3, 5-diiodothyropropionic acid (DITPA). J Mol Cell Cardiol 32:1939-1953, 2000
62. Nediani C, Formigli LL, Perna AM, et al. Early changes induced in the left ventricle by pressure overload. An experimental study on swine heart. J Mol Cell Cardiol 32:131-142, 2000
63. 2+ leak in intact ventricular myocytes from rabbits in heart failure. Circ Res 93:592-594, 2003
64. Gupta RC, Mishra S, Rastogi S, et al. Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am J Physiol Heart Circ Physiol 285:H2373-H2381, 2003
65. Schwinger RHG, Bundgaard Muller-Ehmsen J, et al. The Na, K-ATPase in the failing human heart. Cardiovasc Res 57:913-920, 2003
66. + transport mechanisms in cardiac hypertrophy and failure. J Mol Cell Cardiol 35:5-25, 2003
67. Despa S, Islam MA, Weber CR, et al. Intracellular Na(+) concentration is elevated in heart failure but Na/K pump function is unchanged. Circulation 105:2543-2548, 2002
68. 2+ exchanger protein levels in human heart failure. Circulation 99:2105-2112, 1999
69. 2+ exchange during cardiac hypertrophy after myocardial infarction. Circ Res 91:323-330, 2002
70. +-ATPase alpha 1-but not alpha 3-isoform. Am J Physiol Heart Circ Physiol 266:H1221-H1227, 1994
71. +-ATPase isoforms in myocardium. Isoform change in deoxycorticosterone acetate-salt hypertension. Circ Res 74:669-678, 1994
72. +-ATPase alpha 2- but not alpha 1-isoform abundance in heart, muscle, and brain. Am J Physiol Cell Physiol 260:C958-C964, 1991
73. Allen PD, Schmidt TA, Marsh JD, Kjeldsen K. Na,K-ATPase expression in normal and failing human left ventricle. Basic Res Cardiol 87 (Suppl):87-94, 1992
74. +-ATPase in tachycardia induced cardiomyopathy. J Mol Cell Cardiol 24:277-294, 1992
75. +-ATPase subunit isoforms at mRNA and protein levels in rat myocardium. J Mol Cell Cardiol 26:591-600, 1994
76. Ming Z, Nordin C, Siri F, et al. Reduced calcium current density in single myocytes isolated from hypertrophied failing guinea pig hearts. J Mol Cell Cardiol 26:1133-1143, 1994
77. Rannou F, Sainte-Beuve C, Oliviero P, et al. The effects of compensated cardiac hypertrophy on dihydropyridine and ryanodine receptors in rat, ferret and guinea-pig hearts. J Mol Cell Cardiol 27:1225-1234, 1995
78. 2+ exchanger in end-stage human heart failure. Circ Res 75:443-453, 1994
79. Moalic JM, Charlemagne D, Mansier P, et al. Cardiac hypertrophy and failure-a disease of adaptation. Modifications in membrane proteins provide a molecular basis for arrhythmogenicity. Circulation 87 (Suppl IV):21-26, 1993
80. Eble DM, Walker JD, Mukherjee R, et al. Myosin heavy chain synthesis is increased in a rabbit model of heart failure. Am J Physiol Heart Circ Physiol 272:H969-H978, 1997
81. Kuang SQ, Yu JD, Lu L, et al. Identification of a novel missense mutation in the cardiac beta-myosin heavy chain gene in a Chinese patient with sporadic hypertrophic cardiomyopathy. J Mol Cell Cardiol 28:1879-1883, 1996
82. Hasenfuss G, Mulieri LA, Leavitt BJ, et al. Contractile protein function in failing and nonfailing human myocardium. Basic Res Cardiol 87 (Suppl 1):107-116, 1992
83. Eble DM, Spinale FG. Contractile and cytoskeletal content, structure, and mRNA levels with tachycardia-induced cardiomyopathy. Am J Physiol Heart Circ Physiol 268:H2426-H2439, 1995
84. Swoap SJ, Haddad F, Bodell P, et al. Control of beta-myosin heavy chain expression in systemic hypertension and caloric restriction in the rat heart. Am J Physiol Cell Physiol 269:C1025-C1033, 1995
85. Imamura T, McDermott PJ, Kent RL, et al. Acute changes in myosin heavy chain synthesis rate in pressure versus volume overload. Circ Res 75:418-425, 1994
86. Rupp H, Elimban V, Dhalla NS. Modification of subcellular organelles in pressure-overloaded heart by etomoxir, a carnitine palmitoyltransferase I inhibitor. FASEB J 6:2349-2353, 1992
87. Toffolo RL, Ianuzzo CD. Myofibrillar adaptations during cardiac hypertrophy. Mol Cell Biochem 131:141-149, 1994
88. Schwartz K. Contractile protein gene expression in the hypertrophied heart. Can J Cardiol 9 (Suppl F):12-16, 1993
89. Liu LM, Kato M, Takeda N. Alterations of myosin isoenzymes and ADP/ATP carrier in Goldblatt hypertensive rats. Exp Clin Cardiol 2:199-203, 1997
90. 2+ and calmodulin. Can J Physiol Pharmacol 72:1368-1376, 1994
91. Morano I, Hadicke K, Grom S, et al. Titin, myosin light chains and C-protein in the developing and failing human heart. J Mol Cell Cardiol 26:361-368, 1994
92. Morano I, Hadlicke K, Haase H, et al. Changes in essential myosin light chain isoform expression provide a molecular basis for isometric force regulation in the failing human heart. J Mol Cell Cardiol 29:1177-1187, 1997
93. Gumming DV, Seymour AM, Rix LK, et al. Troponin I and T protein expression in experimental cardiac hypertrophy. Cardioscience 6:65-70, 1995
94. Anderson PA, Greig A, Mark TM, et al. Molecular basis of human cardiac troponin T isoforms expressed in the developing, adult, and failing heart. Circ Res 76:681-686, 1995
95. Mesnard L, Logeart D, Taviaux S, et al. Human cardiac troponin T: Cloning and expression of new isoforms in the normal and failing heart. Circ Res 76:687-692, 1995
96. Ravkilde J, Nissen H, Horder M, et al. Independent prognostic value of serum creatine kinase isoenzyme MB mass, cardiac troponin T and myosin light chain levels in suspected acute myocardial infarction. Analysis of 28 months of follow-up in 196 patients. J Am Coll Cardiol 25:574-581, 1995
97. Chen Z, Higashiyama A, Yaku H, et al. Altered expression of troponin T isoforms in mild left ventricular hypertrophy in the rabbit. J Mol Cell Cardiol 29:2345-2354, 1997
98. Townsend PJ, Barton PJ, Yacoub MH, et al. Molecular cloning of human cardiac troponin T isoforms: Expression in developing and failing heart. J Mol Cell Cardiol 27:2223-2236, 1995
99. Solaro RJ, Burkart EM. Functional defects in troponin and the systems biology of heart failure. J Mol Cell Cardiol 34:689-693, 2002
100. Torrealba JR, Lozano E, Griffin M, et al. Maximal ATPase activity and calcium sensitivity of reconstituted myofilaments are unaltered by the fetal troponin T re-expressed during human heart failure. J Mol Cell Cardiol 34:797-805, 2002
101. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res 68:905-921, 1991
102. Lindpaintner K, Niedermaier N, Drexler H, et al. Left ventricular remodeling after myocardial infarction: Does the cardiac renin-angiotensin system play a role? J Cardiovas Pharmacol 20 (Suppl 1):S41-S47, 1992
103. Basu S, Sinha SK, Shao Q, et al. Neuropeptide Y modulation of sympathetic activity in myocardial infarction. Am J Coll Cardiol 27:1796-1803, 1996
104. Dostal DE, Baker KM. The cardiac renin-angiotensin system: Conceptual, or a regulator of cardiac function? Circ Res 85:643-650, 1999
105. Lijnen P, Petrov V. Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. J Mol Cell Cardiol 31:949-970, 1999
106. Dostal DE. The cardiac renin-angiotensin system: Novel signaling mechanisms related to cardiac growth and function. Regulatory Peptides 91:1-11, 2000
107. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52:11-34, 2000
108. Hu LW, Benvenuti LA, Liberti EA, et al. Thyroxine-induced cardiac hypertrophy: Influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling. Am J Physiol Regul Integ Comp Physiol 285: R1473-R1480, 2003
109. Wang X, Dhalla NS. Modification of beta-adrenoceptor signal transduction pathway by genetic manipulation and heart failure. Mol Cell Biochem 214:131-155, 2000
110. Ju H, Scammel-LaFleur T, Dixon IM. Altered mRNA abundance of calcium transport genes in cardiac myocytes induced by angiotensin II. J Mol Cell Cardiol 28:1119-1128, 1996
111. Shizukuda Y, Buttrick PM, Geenen DL, et al. Beta-adrenergic stimulation causes cardiocyte apoptosis: Influence of tachycardia and hypertrophy. Am J Physiol Heart Circ Physiol 275:H961-H968, 1998
112. 2+-ATPase in mammalian ventricle. J Pharmacol Exp Therap 286:531-538, 1998
113. 2+ ATPase gene expression in congestive heart failure: Effect of chronic norepinephrine infusion. J Mol Cell Cardiol 30:175-185, 1998
114. Gu X, Bishop SP. Increased protein kinase C and isozyme redistribution in pressure-overload cardiac hypertrophy in the rat. Circ Res 75:926-931, 1994
115. 2+ ATPase (SERCA2) gene expression and calcium reuptake. J Mol Cell Cardiol 28:2467-2477, 1996
116. Rouet-Benzineb P, Gontero B, Dreyfuss P, et al. Angiotensin II induces nuclear factor-kappa B activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway. J Mol Cell Cardiol 32:1767-1778, 2000
117. Takeishi Y, Bhagwat A, Ball NA, et al. Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure. Am J Physiol Heart Circ Physiol 276:H53-H63, 1999
118. Baines CP, Song C-X, Zheng YT, et al. Protein kinase Cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ Res 92:873-880, 2003
119. English JM, Cobb MH. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 23:40-45, 2002
120. Hagemann C, Blank JL. The ups and downs of MEK kinase interactions. Cell Signaling 13:863-875, 2003
121. Force T, Pombo CM, Avruch J, et al. Stress-activated protein kinases in cardiovascular disease. Circ Res 78:947-953, 1996
122. Dhalla NS, Dixon IM, Rupp H, et al. Experimental congestive heart failure due to myocardial infarction: Sarcolemmal receptors and cation transporters. Basic Res Cardiol 86 (Suppl. 3):13-23, 1991
123. Cheng TO. Cardiac failure in coronary heart disease. Am Heart J 120:396-412, 1990
124. Lerman RH, Apstein CS, Kagan HS, et al. Myocardial healing and repair after experimental infarction in the rabbit. Circ Res 53:378-388, 1983
125. Cox MM, Berman I, Myerburg RJ, et al. Morphometric mapping of regional myocyte diameters after healing of myocardial infarction in cats. J Mol Cell Cardiol 23:127-135, 1991
126. Vanoli E, De Ferrari GM, Stramba-Badiale M, et al. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res 68:1471-1481, 1991
127. Sabbah HN, Kono T, Stein PD, et al. Left ventricular shape changes during the course of evolving heart failure. Am J Physiol Heart Circ Physiol 263:H266-H270, 1992
128. McDonald KM, Francis GS, Carlyle PF, et al. Memodynamic, left ventricular structural and hormonal changes after discrete myocardial damage in the dog. J Am Coll Cardiol 19:460-467, 1992
129. Jugdutt BI, Schwarz-Michorowski BL, Khan MI. Effect of long-term captopril therapy on left ventricular remodeling and function during healing of canine myocardial infarction. J Am Coll Cardiol 19:713-721, 1992
130. Connelly CM, Ngoy S, Schoen FJ, et al. Biomechanical properties of reperfused transmural myocardial infarcts in rabbits during the first week after infarction. Implications for left ventricular rupture. Circ Res 71:401-413, 1992
131. Knowlton AA, Connelly CM, Romo GM, et al. Rapid expression of fibronectin in the rabbit heart after myocardial infarction with and without reperfusion. J Clin Invest 89:1060-1068, 1992
132. Kozlovskis PL, Gerdes AM, Smets M, et al. Regional increase in isolated myocyte volume in chronic myocardial infarction in cats. J Mol Cell Cardiol 23:1459-1466, 1991
133. Johns TN, Olson BJ. Experimental myocardial infarction. I. A method of coronary occlusion in small animals. Ann Surg 140:675-682, 1954
134. Selye H, Bajusz E, Grasso S, et al. Simple techniques for the surgical occlusion of coronary vessels in the rat. Angiology 11:398-407, 1960
135. Fishbein MC, Maclean D, Maroko PR. Experimental myocardial infarction in the rat: Qualitative and quantitative changes during pathologic evolution. Am J Pathol 90:57-70, 1978
136. Pfeffer MA, Pfeffer JM, Fishbein MC, et al. Myocardial infarct size and ventricular function in rats. Circ Res 44:503-512, 1979
137. Geenen DL, Malhotra A, Liang D, et al. Ventricular function and contractile proteins in the infarcted overloaded rat heart. Cardiovasc Res 25:330-336, 1991
138. 2+ channels in experimental cardiac failure. Am J Physiol Heart Circ Physiol 261: H1979-H1987, 1991
139. Chasteney EA, Liang CS, Hood WB Jr. Beta-adrenoceptor and adenylate cyclase function in the infarct model of rat heart failure. Proc Soc Exp Biol Med 200:90-94, 1992
140. Qi XL, Stewart DJ, Gosselin H, et al. Improvement of endocardial and vascular endothelial function on myocardial performance by captopril treatment in postinfarct rat hearts. Circulation 100:1338-1345, 1999
141. Rowley KG, Tung LH, Hodsman GP, et al. Altered alpha 1-adrenoceptor- mediated responses in atria of rats with chronic left ventricular infarction. J Cardiovasc Pharmacol 17:474-479, 1991
142. Rubin SA, Fishbein MC, Swan HJ. Compensatory hypertrophy in the heart after myocardial infarction in the rat. J Am Coll Cardiol 1:1435-1441, 1983
143. Anversa P, Beghi C, Kikkawa Y, et al. Myocardial infarction in rats. Infarct size, myocyte hypertrophy, and capillary growth. Circ Res 58:26-37, 1986
144. Anversa P, Beghi C, McDonald SL, et al. Morphometry of right ventricular hypertrophy induced by myocardial infarction in the rat. Am J Pathol 116:504-513, 1984
145. Zimmer HG, Gerdes AM, Lortet S, et al. Changes in heart function and cardiac cell size in rats with chronic myocardial infarction. J Mol Cell Cardiol 22:1231-1243, 1990
146. Fletcher PJ, Pfeffer JM, Pfeffer MA, et al. Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction. Effects on systolic function. Circ Res 49:618-626, 1981
147. Pfeffer JM, Pfeffer MA, Fletcher PJ, et al. Ventricular performance in rats with myocardial infarction and failure. Am J Med 76:99-103, 1984
148. DeFelice A, Frering R, Horan P. Time course of hemodynamic changes in rats with healed severe myocardial infarction. Am J Physiol Heart Circ Physiol 257: H289-H296, 1989
149. Geenen DL, Malhotra A, Scheuer H. Regional variation in rat cardiac myosin isoenzymes and ATPase activity after infarction. Am J Physiol Heart Circ Physiol 256: H745-H750, 1989
150. Liu X, Shao Q, Dhalla NS. Myosin light chain phosphorylation in cardiac hypertrophy and failure due to myocardial infarction. J Mol Cell Cardiol 27:2613-2621, 1995
151. Akiyama K, Akopian G, Jinadasa P, et al. Myocardial infarction and regulatory myosin light chain. J Mol Cell Cardiol 29:2641-2652, 1997
152. Li P, Hofman PA, Li B, et al. Myocardial infarction alters myofilament calcium sensitivity and mechanical behavior of myocytes. Am J Physiol Heart Circ Physiol 272: H360-H370, 1997
153. Fellenius E, Hansen CA, Mjos O, et al. Chronic infarction decreases maximum cardiac work and sensitivity of heart to extracellular calcium. Am J Physiol Heart Circ Physiol 249:H80-H87, 1985
154. De Tombe PP, Wannenburg T, Fan D, et al. Right ventricular contractile protein function in rats with left ventricular myocardial infarction. Am J Physiol Heart Circ Physiol 271:H73-H79, 1996
155. Buttrick P, Perla C, Maholtra A, et al. Effects of chronic dobutamine on cardiac mechanics and biochemistry after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 260:H473-H479, 1991
156. Drexler H, Depenbusch JW, Truog AG, et al. Effects of diltiazem on cardiac function and regional blood flow at rest and during exercise in a conscious rat preparation of chronic heart failure (myocardial infarction). Circulation 71:1262-1270, 1985
157. Pelouch V, Dixon IM, Sethi R, et al. Alteration of collagenous protein profile in congestive heart failure secondary to myocardial infarction. Mol Cell Biochem 129:121-131, 1994
158. Lui K, Jackson M, Sowa MG, et al. Modification of the extracellular matrix following myocardial infarction monitored by FTIR spectroscopy. Biochim Biophys Acta 1315:73-77, 1996
159. Gallagher AM, Omens JH, Chu LL, et al. Alterations in collagen fibrillar structure and mechanical properties of the healing scar following myocardial infarction. Cardiovasc Pathobiol 1:25-36, 1997
160. Eberli FR, Sam F, Ngoy S, et al. Left-ventricular structural and functional remodeling in the mouse after myocardial infarction: Assessment with the isovolumetrically-contracting Langendorff heart. J Mol Cell Cardiol 30:1443-1447, 1998
161. Gosselin H, Qi X, Rouleau JL. Correlation between cardiac remodelling, function, and myocardial contractility in rat hearts 5 weeks after myocardial infarction. Can J Physiol Pharmacol 76:53-62, 1998
162. Siminiak T, Smielecki J, Dye JF, et al. Detection of the soluble adhesion molecules L-selectin and vascular cell adhesion molecule 1 during acute myocardial infarction. Exp Clin Cardiol 2:215-218, 1997
163. Takemura G, Ohno M, Hayakawa Y, et al. Role of apoptosis in the disappearance of infiltrated and proliferated interstitial cells after myocardial infarction. Circ Res 82:1130-1138, 1998
164. Litwin SE, Raya TE, Anderson PG, et al. Induction of myocardial hypertrophy after coronary ligation in rats decreases ventricular dilatation and improves systolic function. Circulation 84:1819-1827, 1991
165. Ganguly PK, Dhalla KS, Shao Q, et al. Differential changes in sympathetic activity in left and right ventricles in congestive heart failure after myocardial infarction. Am Heart J 133:340-345, 1997
166. Oie E, Bjonerheim R, Grogaard HK, et al. ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats. Am J Physiol Heart Circ Physiol 275:H868-H877, 1998
167. Kramer JH, Phillips TM, Weglicki WB. Magnesium-deficiency-enhanced post-ischemic myocardial injury is reduced by substance P receptor blockade. J Mol Cell Cardiol 29:97-110, 1997
168. Ontkean M, Gay R, Greenberg B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res 69:1088-1096, 1991
169. Mendez RE, Pfeffer JM, Ortola FV, et al. Atrial natriuretic peptide transcription, storage, and release in rats with myocardial infarction. Am J Physiol Heart Circ Physiol 253:H1449-H1455, 1987
170. Drexler H, Hirth C, Stasch HP, et al. Vasodilatory action of endogenous atrial natriuretic factor in a rat model of chronic heart failure as determined by monoclonal ANF antibody. Circ Res 66:1371-1380, 1990
171. Hodsman GP, Kohzuki M, Howes LG, et al. Neurohumoral responses to chronic myocardial infarction in rats. Circulation 78:376-381, 1988
172. Tsunoda K, Hodsman GP, Sumithran E, et al. Atrial natriuretic peptide in chronic heart failure in the rat: A correlation with ventricular dysfunction. Circ Res 59:256-261, 1986
173. Shao Q, Takeda N, Temsah R, et al. Prevention of hemodynamic changes due to myocardial infarction by early treatment of rats with imidapril. Cardiovasc Pathobiol 1:180-186, 1996
174. Dixon IM, Lee SL, Dhalla NS. Nitrendipine binding in congestive heart failure due to myocardial infarction. Circ Res 66:782-788, 1990
175. Afzal N, Dhalla NS. Differential changes in left and right ventricular SR calcium transport in congestive heart failure. Am J Physiol Heart Circ Physiol 262:H868-H874, 1992
176. Yamaguchi F, Sanbe A, Takeo S. Cardiac sarcoplasmic reticular function in rats with chronic heart failure following myocardial infarction. J Mol Cell Cardiol 29:753-763, 1997
177. 2+ pump ATPase activity in congestive heart failure due to myocardial infarction. Can J Cardiol 12:1065-1073, 1996
178. 2+-pump ATPase in congestive heart failure due to myocardial infarction. Mol Cell Biochem 163/164:285-290, 1996
179. 2+ exchanger genes between adjacent and remote noninfarcted myocardium after myocardial infarction. J Mol Cell Cardiol 29:255-264, 1997
180. Dixon IM, Dhalla NS. Alterations in cardiac adrenoceptors in congestive heart failure secondary to myocardial infarction. Cor Art Disease 2:805-814, 1991
181. Sethi R, Dhalla KS, Beamish RE, et al. Differential changes in left and right ventricular adenylyl cyclase activities in congestive heart failure. Am J Physiol Heart Circ Physiol 272:H884-H893, 1997
182. +-ATPase activity in congestive heart failure due to myocardial infarction. Am J Physiol Cell Physiol 262: C664-C671, 1992
183. +-pump capacity in congestive heart failure following myocardial infarction in rats. J Mol Cell Cardiol 30:1311-1328, 1998
184. Dixon IM, Hata T, Dhalla NS. Sarcolemmal calcium transport in congestive heart failure due to myocardial infarction in rats. Am J Physiol Heart Circ Physiol 262:H1387-H1394, 1992
185. Anand IS, Liu D, Chugh SS, et al. Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction. Circulation 96:3974-3984, 1997
186. Kiseleva I, Kamkin A, Pylaev A, et al. Electrophysiological properties of mechanosensitive atrial fibroblasts from chronic infarcted rat heart. J Mol Cell Cardiol 30:1083-1093, 1998
187. Zhang X-Q, Moore RL, Tillottson DL, et al. Calcium currents in postinfarction rat cardiac myocytes. Am J Physiol Cell Physiol 269:C1464-C1473, 1995
188. 2+-dependent outward currents in myocytes from epicardial border zone of 5-day infarcted canine heart. Am J Physiol Heart Circ Physiol 273:H1386-H1394, 1997
189. 2+ contents in postinfarction myocytes. Am J Physiol Cell Physiol 271:C1800-C1807, 1996
190. + channel genes in left ventricular remodeled myocardium after experimental myocardial infarction. Circ Res 79:669-675, 1996
191. Ren B, Lukas A, Shao Q, et al. Electrocardiographic changes and mortality due to myocardial infarction in rats with or without imidapril treatment. J Cardiovas Pharmacol Therapeut 3:11-22, 1998
192. Schoemaker RG, Debets JJ, Struyker-Boudier HA, et al. Delayed but not immediate captopril therapy improves cardiac function in conscious rats, following myocardial infarction. J Mol Cell Cardiol 23:187-197, 1991
193. Jugdutt BI, Schwarz-Michorowski BL, Khan MI. Effect of long-term captopril therapy on left ventricular remodeling and function during healing of canine myocardial infarction. J Am Coll Cardiol 19:713-721, 1992
194. Dixon IM, Ju H, Jassal DS, et al. Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction. Mol Cell Biochem 165:31-45, 1996
195. van Krimpen C, Smits JF, Cleutjens JP, et al. DNA synthesis in the non-infarcted cardiac interstitium after left coronary artery ligation in the rat: Effects of captopril. J Mol Cell Cardiol 23:1245-1253, 1991
196. McDonald KM, Chu C, Francis JS, et al. Effect of delayed intervention with ACE-inhibitor therapy on myocyte hypertrophy and growth of the cardiac interstitium in the rat model of myocardial infarction. J Mol Cell Cardiol 29:3202-3210, 1997
197. Gonzalez W, Beslot F, Laboulandine I, et al. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction. J Pharmacol Exptl Therap 278:573-581, 1996
198. Kuizinga MC, Smits JF, Arends JW, et al. AT2 receptor blockade reduces cardiac interstitial cell DNA synthesis and cardiac function after rat myocardial infarction. J Mol Cell Cardiol 30:425-434, 1998
199. Ford WR, Khan MI, Jugdutt BI. Effect of the novel angiotensin II type 1 receptor antagonist L-158,809 on acute infarct expansion and acute anterior myocardial infarction in the dog. Can J Cardiol 14:73-80, 1998
200. Raya TE, Gay RG, Aguirre M, et al. Importance of venodilatation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats: A comparison of captopril and hydralazine. Circ Res 64:330-337, 1989
201. Michel JB, Lattion AL, Salzmann JL, et al. Hormonal and cardiac effects of converting enzyme inhibition in rat myocardial infarction. Circ Res 62:641-650, 1988
202. Wollert KC, Studer R, von Bulow B, et al. Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition. Circulation 90:2457-2467, 1994
203. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99:1926-1935, 1997
204. Sanbe A, Takeo S. Long-term treatment with angiotensin I-converting enzyme inhibitors attenuates the loss of cardiac beta-adrenoceptor responses in rats with chronic heart failure. Circulation 92:2666-2675, 1995
205. Litwin SE, Morgan JP. Captopril enhances intracellular calcium handling and beta-adrenergic responsiveness of myocardium from rats with postinfarction failure. Circ Res 71:797-807, 1992
206. Gay RG, Raya TE, Goldman S. Chronic propranolol treatment promotes left ventricular dilation without altering systolic function after large myocardial infarction in rats. J Cardiovas Pharmacol 16:529-536, 1990
207. Hu K, Gaudron P, Ertl G. Long-term effects of beta-adrenergic blocking agent treatment on hemodynamic function and left ventricular remodeling in rats with experimental myocardial infarction: importance of timing of treatment and infarct size. J Am Coll Cardiol 31:692-700, 1998
208. Sharpe N. Beta-blockers in heart failure. Future directions. Eur Heart J 17 (Suppl B):39-42, 1996
209. Bohm M, Deutsch HJ, Hartmann D, et al. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol 30:992-996, 1997
210. Savonitto S, Ardissino D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris results of the international multicenter angina exercise (IMAGE) study. J Am Coll Cardiol 27:311-316, 1996
211. Fan T-HM, Frantz RP, Elam H, et al. Reductions of myocardial Na-K-ATPase activity and ouabain binding sites in heart failure: Prevention by nadolol. Am J Physiol Heart Circ Physiol 265:H2086-H2093, 1993
212. Sigmund M, Jakob H, Becker H, et al. Effects of metoprolol on myocardial beta-adrenoceptors and Gi alpha-proteins in patients with congestive heart failure. Eur J Clin Pharmacol 51:127-132, 1996
213. Levett JM, Marinelli CC, Lund DD, et al. Effects of beta-blockade on neurohumoral responses and neurochemical markers in pacing-induced heart failure. Am J Physiol Heart Circ Physiol 266:H468-H475, 1994
214. Levy S. Secondary prevention after myocardial infarction: In favor of beta-blockers. J Cardiovasc Pharmacol 16:S50-S54, 1990
215. Leitch JW, McElduff P, Dobson A, et al. Outcome with calcium channel antagonists after myocardial infarction: A community-based study. J Am Coll Cardiol 31:111-117, 1998
216. Gilligan DM, Chan WL, Joshi J, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol 21:1672-1679, 1993
217. Liu P. Reappraisal of calcium channel blockers in heart failure. Can J Cardiol 12:9F-13F, 1996
218. Shimoyama H, Sabbah HN, Tanimura M, et al. Short-term hemodynamic effects of mibefradil in dogs with chronic heart failure: Comparison with diltiazem. J Pharmacol Exptl Therap 285:746-752, 1998
219. Orenstein TL, Parker TG, Butany JW, et al. Favorable left ventricular remodeling following large myocardial infarction by exercise training. Effect on ventricular morphology and gene expression. J Clin Invest 96:858-866, 1995
220. Cittadini A, Grossman JD, Napoli R, et al. Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am Coll Cardiol 29:1109-1116, 1997
221. Tomanek RJ, Zimmerman MB, Suvarna PR, et al. A thyroid hormone analog stimulates angiogenesis in the post-infarcted rat heart. J Mol Cell Cardiol 30:923-932, 1998
222. Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol 148:291-300, 1996
223. Ruzicka M, Yuan B, Harmsen E, et al. The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker. Circulation 87:921-930, 1993
224. Ruzicka M, Skarda V, Leenen FH. Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats Circulation 92:3568-3573, 1995
225. Ruzicka M, Leenen FH. Relevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy. Circulation 91:16-19, 1995
226. Zolk O, Flesch M, Schnabel P et al. Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats. Br J Pharmacol 123:405-412, 1998
227. Fischer TA, Singh K, O'Hara DS, et al. Role of AT1 and AT2 receptors in regulation of MAPKs and MKP-1 by ANG II in adult cardiac myocytes. Am J Physiol Heart Circ Physiol 275:H906-H916, 1998
228. van Gilst WH, Kingma JH, Peels JH, et al. Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the captopril and thrombolysis study (CATS). J Am Coll Cardiol 28:114-121, 1996
229. Lang RM, Elkayam U, Yellen LG, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The losartan pilot exercise study investigators. J Am Coll Cardiol 30:983-991, 1997
230. Yang X, Zhu Q, Fong J, et al. Enalaprilat, an angiotensin-converting enzyme inhibitor, enhances functional preservation during long-term cardiac preservation. Possible involvement of bradykinin and PKC. J Mol Cell Cardiol 28:1445-1452, 1996
231. Pfeffer M, Lamas GA, Vaughan DE, et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 319:80-86, 1988
232. 2+-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy. J Hypertension 15:1001-1009, 1997
233. Jakob H, Sigmund M, Eschenhagen T, et al. Effect of captopril on myocardial beta-adrenoceptor density and Gi alpha-proteins in patients with mild to moderate heart failure due to dilated cardiomyopathy. Eur J Clin Pharmacol 47:389-394, 1995
234. Wang X, Sentex E, Chapman D, et al. Alterations of adenylyl cyclase and G proteins in aortocaval shunt-induced heart failure. Am J Physiol Heart Circ Physiol 287:H118-H125, 2004
235. Wang X, Sentex E, Saini HK, et al. Upregulation of β-adrenergic receptors in heart failure due to volume overload. Am J Physiol Heart Circ Physiol 289:H151-H159, 2005
236. Wang J, Liu X, Ren B, et al. Modification of myosin gene expression by imidapril in failing heart due to myocardial infarction. J Mol Cell Cardiol 34:847-857, 2002
237. Wang J, Liu X, Sentex E, et al. Increased expression of protein kinase C isoforms in heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol 284:H2277-H2287, 2003
238. 2+/Calmodulin-dependent protein kinase is altered in heart failure. Circ Res 86:596-605, 2000
239. Guo X, Chapman D, Dhalla NS. Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losartan. J Mol Cell Cardiol 254:163-172, 2003
240. Yu CH, Panagia V, Tappia PS, et al. Alterations of sarcolemmal phospholipase D and phosphatidate phosphohydrolase in congestive heart failure. Biochem Biophys Acta 1584:65-72, 2002
241. Tappia PS, Liu SY, Shatadal S, et al. Changes in sarcolemmal PLC isoenzymes in postinfarct congestive heart failure: Partial correction by imidapril. Am J Physiol 277: H40-H49, 1999
242. Tappia PS, Yu CH, Di Nardo P, et al. Depressed responsiveness of phospholipase C isoenzymes to phosphatidic acid in congestive heart failure. J Mol Cell Cardiol 33:431-440, 2001
243. Wang J, Guo X, Dhalla NS. Modification of myosin proteins and gene expression in failing hearts due to myocardial infarction by enalapril and losartan. Biochem Biophys Acta 1690:177-184, 2004
244. Saini HK, Shao Q, Musat S, et al. Imidapril treatment improves the attenuated inotropic and intracellular calcium responses to ATP in heart failure due to myocardial infarction. Br J Pharmacol 144:202-211, 2005
245. 2+ transport and gene expression in congestive heart failure are modified by imidapril treatment. Am J Physiol Heart Circ Physiol 288:H1674-H1682, 2005
246. 2+ exchanger expression in heart failure by blockade of renin-angiotensin system. Am J Physiol Heart Circ Physiol 288: H2637-H2646, 2005
247. Ren B, Shao Q, Ganguly PK, et al. Influence of long term treatment of imidapril on mortality, cardiac function and gene expression in congestive heart failure due to myocardial infarction. Can J Physiol Pharmacol 82:1118-1127, 2004
248. Sethi R, Shao Q, Ren B, et al. Changes in β-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system. Mol Cell Biochem 263:11-20, 2004
249. Guo X, Saini HK, Wang J, et al. Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin-angiotensin system. Expert Rev Cardiovasc Ther 3:717-732, 2005
250. 2+/calmodulin-dependent protein kinase II in vivo. Mol Endocrinol 17:183-192, 2003
251. Miyamoto M, del Monte F, Schmidt U, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci 97:793-798, 2000
252. Houser SR, Piacentino V 3rd, Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol 32:1595-1607, 2000
253. Sethi R, Dhalla KS, Ganguly PK, et al. Beneficial effects of propionyl L-carnitine on sarcolemmal changes in congestive heart failure due to myocardial infarction. Cardiovasc Res 42:607-615, 1999
254. Sethi R, Wang X, Ferrari R, et al. Improvement of cardiac function and beta-adrenergic signal transduction by propionyl L-carnitine in congestive heart failure due to myocardial infarction. Coron Art Dis 15:65-71, 2004
255. Mengi SR, Dhalla NS. Carnitine palmitoyltransferase-1, a new target for the treatment of heart failure. Perspectives on a shift in myocardial metabolism as a therapeutic intervention. Am J Cardiovasc Drugs 4:201-209, 2004
256. Gumina RJ, Mizumura T, Beier N, et al. A new sodium/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion. J Pharmacol 286:175-183, 1998
257. + exchange: Structure, regulation, and its role in heart disease. Circ Res 85:777-786, 1999
258. + exchange inhibition attenuates hypertrophy and heart failure in 1-wk postinfarction rat myocardium. Am J Physiol Heart Circ Physiol 278:H300-H304, 2000
259. + exchange inhibitor cariporide. J Pharmacol Exp Therap 298:469-476, 2001
260. + exchange inhibition reduces hypertrophy and heart failure after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 280:H738-H475, 2001